Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Issues Earnings Results, Misses Estimates By $0.01 EPS
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) issued its earnings results on Tuesday. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.01, Bloomberg Earnings reports.
Aimmune Therapeutics (NASDAQ AIMT) traded down 7.50% on Wednesday, hitting $19.00. The stock had a trading volume of 446,004 shares. The stock’s market capitalization is $956.50 million. Aimmune Therapeutics has a 1-year low of $12.34 and a 1-year high of $27.31. The company has a 50-day moving average price of $20.77 and a 200-day moving average price of $19.92.
In related news, insider Douglas T. Sheehy sold 7,460 shares of the business’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $21.66, for a total value of $161,583.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Susan E. Barrowcliffe sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $20.26, for a total value of $303,900.00. Following the completion of the sale, the insider now owns 15,000 shares of the company’s stock, valued at approximately $303,900. The disclosure for this sale can be found here. In the last quarter, insiders have sold 188,470 shares of company stock valued at $3,942,092. Corporate insiders own 24.56% of the company’s stock.
A number of brokerages have recently issued reports on AIMT. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Tuesday, May 16th. ValuEngine cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 27th. Wedbush reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a research report on Monday, July 24th. Finally, Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $33.00.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.